Ad is loading...
LIXT
Price
$1.52
Change
-$0.00 (-0.00%)
Updated
Nov 21 closing price
NTLA
Price
$13.80
Change
-$0.00 (-0.00%)
Updated
Nov 21 closing price
90 days until earnings call
Ad is loading...

LIXT vs NTLA

Header iconLIXT vs NTLA Comparison
Open Charts LIXT vs NTLABanner chart's image
Lixte Biotechnology Holdings
Price$1.52
Change-$0.00 (-0.00%)
Volume$27.79K
CapitalizationN/A
Intellia Therapeutics
Price$13.80
Change-$0.00 (-0.00%)
Volume$3.97M
CapitalizationN/A
LIXT vs NTLA Comparison Chart
Loading...
NTLA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
LIXT vs. NTLA commentary
Nov 23, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LIXT is a Hold and NTLA is a Hold.

COMPARISON
Comparison
Nov 23, 2024
Stock price -- (LIXT: $1.63 vs. NTLA: $14.30)
Brand notoriety: LIXT and NTLA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: LIXT: 4% vs. NTLA: 94%
Market capitalization -- LIXT: $3.67M vs. NTLA: $1.46B
LIXT [@Biotechnology] is valued at $3.67M. NTLA’s [@Biotechnology] market capitalization is $1.46B. The market cap for tickers in the [@Biotechnology] industry ranges from $450.11B to $0. The average market capitalization across the [@Biotechnology] industry is $2.63B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

LIXT’s FA Score shows that 0 FA rating(s) are green whileNTLA’s FA Score has 1 green FA rating(s).

  • LIXT’s FA Score: 0 green, 5 red.
  • NTLA’s FA Score: 1 green, 4 red.
According to our system of comparison, NTLA is a better buy in the long-term than LIXT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NTLA’s TA Score shows that 4 TA indicator(s) are bullish.

  • NTLA’s TA Score: 4 bullish, 5 bearish.

Price Growth

LIXT (@Biotechnology) experienced а +0.62% price change this week, while NTLA (@Biotechnology) price change was +2.36% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.38%. For the same industry, the average monthly price growth was -4.87%, and the average quarterly price growth was +4.35%.

Reported Earning Dates

LIXT is expected to report earnings on May 10, 2023.

NTLA is expected to report earnings on Feb 20, 2025.

Industries' Descriptions

@Biotechnology (+2.38% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NTLA($1.46B) has a higher market cap than LIXT($3.67M). LIXT YTD gains are higher at: -35.319 vs. NTLA (-54.739). LIXT has higher annual earnings (EBITDA): -3.98M vs. NTLA (-527.52M). NTLA has more cash in the bank: 658M vs. LIXT (1.64M). LIXT has less debt than NTLA: LIXT (100K) vs NTLA (102M). NTLA has higher revenues than LIXT: NTLA (43.1M) vs LIXT (0).
LIXTNTLALIXT / NTLA
Capitalization3.67M1.46B0%
EBITDA-3.98M-527.52M1%
Gain YTD-35.319-54.73965%
P/E RatioN/AN/A-
Revenue043.1M-
Total Cash1.64M658M0%
Total Debt100K102M0%
FUNDAMENTALS RATINGS
LIXT vs NTLA: Fundamental Ratings
LIXT
NTLA
OUTLOOK RATING
1..100
9559
VALUATION
overvalued / fair valued / undervalued
1..100
71
Overvalued
32
Undervalued
PROFIT vs RISK RATING
1..100
10097
SMR RATING
1..100
10097
PRICE GROWTH RATING
1..100
8894
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NTLA's Valuation (32) in the Biotechnology industry is somewhat better than the same rating for LIXT (71) in the null industry. This means that NTLA’s stock grew somewhat faster than LIXT’s over the last 12 months.

NTLA's Profit vs Risk Rating (97) in the Biotechnology industry is in the same range as LIXT (100) in the null industry. This means that NTLA’s stock grew similarly to LIXT’s over the last 12 months.

NTLA's SMR Rating (97) in the Biotechnology industry is in the same range as LIXT (100) in the null industry. This means that NTLA’s stock grew similarly to LIXT’s over the last 12 months.

LIXT's Price Growth Rating (88) in the null industry is in the same range as NTLA (94) in the Biotechnology industry. This means that LIXT’s stock grew similarly to NTLA’s over the last 12 months.

LIXT's P/E Growth Rating (100) in the null industry is in the same range as NTLA (100) in the Biotechnology industry. This means that LIXT’s stock grew similarly to NTLA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NTLA
RSI
ODDS (%)
Bullish Trend 2 days ago
82%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
79%
Momentum
ODDS (%)
Bearish Trend 2 days ago
87%
MACD
ODDS (%)
Bearish Trend 2 days ago
85%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
87%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
89%
Advances
ODDS (%)
Bullish Trend 12 days ago
78%
Declines
ODDS (%)
Bearish Trend 3 days ago
86%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
89%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Ad is loading...
NTLA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FSSMX48.950.81
+1.68%
Fidelity Stock Selector Mid Cap
RYTTX351.133.70
+1.06%
Rydex S&P 500 2x Strategy A
TRZQX39.170.32
+0.82%
T. Rowe Price Equity Income Z
SGFCX41.600.18
+0.43%
Sparrow Growth C
COSOX10.470.02
+0.19%
Columbia Overseas Core Institutional 3

LIXT and

Correlation & Price change

A.I.dvisor tells us that LIXT and IBIO have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that LIXT and IBIO's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LIXT
1D Price
Change %
LIXT100%
+2.01%
IBIO - LIXT
29%
Poorly correlated
+11.87%
NTLA - LIXT
28%
Poorly correlated
+5.18%
BBIO - LIXT
27%
Poorly correlated
+0.87%
PMN - LIXT
26%
Poorly correlated
-4.23%
ITOS - LIXT
26%
Poorly correlated
+3.57%
More

NTLA and

Correlation & Price change

A.I.dvisor indicates that over the last year, NTLA has been closely correlated with VCYT. These tickers have moved in lockstep 69% of the time. This A.I.-generated data suggests there is a high statistical probability that if NTLA jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NTLA
1D Price
Change %
NTLA100%
+5.18%
VCYT - NTLA
69%
Closely correlated
-0.66%
EDIT - NTLA
68%
Closely correlated
-1.66%
BEAM - NTLA
67%
Closely correlated
-3.72%
CRSP - NTLA
63%
Loosely correlated
-2.05%
PRME - NTLA
58%
Loosely correlated
-0.67%
More